Application of trigonelline in preparation of medicine for preventing or treating prostatic hyperplasia

A technology of prostatic hyperplasia and trigonelline, applied in the direction of drug combination, pharmaceutical formula, plant raw materials, etc., to achieve the effect of reducing the wet weight of the prostate, reducing the prostatic hyperplasia, and reducing the PSA level

Active Publication Date: 2021-06-04
NINGXIA MEDICAL UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether trigonelline has an im...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trigonelline in preparation of medicine for preventing or treating prostatic hyperplasia
  • Application of trigonelline in preparation of medicine for preventing or treating prostatic hyperplasia
  • Application of trigonelline in preparation of medicine for preventing or treating prostatic hyperplasia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Rat benign prostatic hyperplasia model construction and pathological detection

[0022] 1. Materials and methods

[0023] 1.1 Animal Selection

[0024] 60 clean, healthy, male SD rats, weighing (250±20) g (Ningxia Medical University Experimental Animal Center, certificate number SYXK (Ning) 2009-0001). Raised in barrier animal experimental facilities [SYXK (black) 2016001], and given humane care according to the 3R principles used in experimental animals.

[0025] 1.2 Drugs and reagents

[0026] Trigonelline hydrochloride (Beijing Suolaibao Technology Co., Ltd., purity: 98%, batch number: 20201025); testosterone propionate injection (Tianjin Jinyao Pharmaceutical Co., Ltd., batch number 1706061); finasteride tablets ( Hangzhou Merck Pharmaceutical Co., Ltd., batch number R008311), prostate-specific antigen (PSA) (Shanghai Jianglai Biotechnology Co., Ltd., batch number: JL10345)

[0027] 1.3 Instruments

[0028] -20°C low-temperature refrigerator (Hefei Ro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of trigonelline in preparation of a medicine for preventing or treating prostatic hyperplasia. A rat benign prostatic hyperplasia (BPH) model is established through a testosterone propionate induction method, and a method of histology and molecular biology is adopted to verify that the trigonelline can significantly reduce the prostate wet weight and reduce the prostate index; the prostatic hyperplasia is observed to be obviously relieved in form; the PSA level in serum is obviously reduced; and it shows that the trigonelline has an improvement effect on BPH of rats and can be used for preparing the medicine for preventing or treating the prostatic hyperplasia.

Description

technical field [0001] The invention relates to the technical field of drug application, in particular to the application of trigonelline in the preparation of drugs for preventing or treating benign prostatic hyperplasia. Background technique [0002] BPH generally refers to benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH) is a common progressive disease in middle-aged and elderly men. Due to the increasingly prominent problem of population aging, the incidence of BPH has increased significantly. Studies have found that the incidence of BPH in men over 50 years old is about 50%, and that of men over 80 years old is as high as 90%. As the excessive enlargement of prostate tissue further leads to bladder outlet obstruction, about 50% of men over 60 years old show different symptoms. Degree of clinical symptoms, such as urinary frequency, urgency, urinary weakness, urinary retention or occasional urge incontinence secondary to bladder detrusor hypersensitivit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/455A61K36/48A61P13/08A61K131/00
CPCA61K31/455A61K36/48A61P13/08
Inventor 郑婕周茹袁玲安卅马文龙王玉琴
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap